IMPE2023 Controversies T2D treatment – should we wait for approved medication? (2 abstracts)
Clinicians should muster the courage to use off-label medications when treating young patients with type 2 diabetes.
Jacqueline Curran
Perth Children's Hospital, Perth, Australia
The medical world has been undertreating youth onset type 2 diabetes for decades. With the number of youths affected by this devastating disease increasing worldwide there is no room in modern medicine for clinical inertia. Intensified therapy to treat-to-target rather than treat-to-failure is best practice. Clinicians caring for youth affected by type 2 diabetes need to be prepared to muster the courage and ask for early access to off-label medications.
Article tools
My recent searches
My recently viewed abstracts
Authors
IMPE Abstracts
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more